NASDAQ:NMAD Lixte Biotechnology Q3 2026 Earnings Results & Report $2.63 -0.22 (-7.72%) As of 11:01 AM Eastern Lixte Biotechnology reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$0.74, while revenue was $472 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market OpensConference Call7:00 AM ET Lixte Biotechnology EPS ResultsActual EPS-$0.74Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALixte Biotechnology Revenue ResultsActual Revenue$472 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Lixte Biotechnology Q3 2026 Earnings FAQ Did Lixte Biotechnology beat earnings estimates for Q3 2026? Lixte Biotechnology (NASDAQ:NMAD) reported earnings of -$0.74 per share for Q3 2026. The report was announced on Monday, November 16, 2026. What was Lixte Biotechnology's revenue for Q3 2026? Lixte Biotechnology reported revenue of $472 thousand for Q3 2026. Lixte Biotechnology Earnings HeadlinesLixte Biotechnology (NASDAQ:NMAD) Shares Up 7.1% - Time to Buy?November 18 at 3:00 AM | americanbankingnews.comNOMAD POWER SOLUTIONS FILES THIRD QUARTER 2026 FORM 10-Q AND PROVIDES BUSINESS UPDATENovember 16 at 5:20 PM | globenewswire.comMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 19 at 1:00 AM | Profits Run (Ad)NOMAD Firms Up Supply Chain for Q1 2027 Production Ramp as Utility RFPs Rise 150% Quarter-over-QuarterNovember 12, 2026 | globenewswire.comNOMAD Power Solutions Appoints Michael Hilmer Executive ChairmanNovember 9, 2026 | globenewswire.comNOMAD Expands Utility Sales Network to 26 States with Two Representative AgreementsOctober 28, 2026 | globenewswire.comSee More Lixte Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lixte Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lixte Biotechnology and other key companies, straight to your email. Email Address About Lixte BiotechnologyLixte Biotechnology (NASDAQ:NMAD) Holdings is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on compounds that target protein phosphatase 2A (PP2A), an enzyme involved in cellular processes that can influence cancer growth and treatment response.The company’s lead investigational candidate, LB-100, is a small-molecule PP2A inhibitor being studied for potential use alongside existing cancer treatments. Lixte has described its approach as aiming to make tumors more responsive to therapies such as chemotherapy and immunotherapy. LB-100 is investigational and has not been approved as a treatment.View Lixte Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going? Upcoming Earnings Agilent Technologies (11/23/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.